Patents by Inventor David Adrianus Theodorus Maria Zuijdgeest
David Adrianus Theodorus Maria Zuijdgeest has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230075527Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).Type: ApplicationFiled: January 30, 2021Publication date: March 9, 2023Inventors: Dan H. BAROUCH, Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Rinke BOS, Frank WEGMANN, David Adrianus Theodorus Maria ZUIJDGEEST, An VANDEBOSCH, Mathieu Claude Michel LE GARS, Jerald C. SADOFF
-
Patent number: 11498944Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).Type: GrantFiled: January 30, 2021Date of Patent: November 15, 2022Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel Le Gars, Jerald C. Sadoff
-
Patent number: 11384122Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).Type: GrantFiled: July 28, 2021Date of Patent: July 12, 2022Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel le Gars, Jerald C. Sadoff
-
Publication number: 20210246170Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).Type: ApplicationFiled: January 30, 2021Publication date: August 12, 2021Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Rinke BOS, Frank WEGMANN, David Adrianus Theodorus Maria ZUIJDGEEST, Dan H. BAROUCH, An VANDEBOSCH, Mathieu Claude Michel le GARS, Jerald C. SADOFF
-
Patent number: 9593159Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. Provided are nucleic acid molecules encoding the binding molecules, their sequences, and compositions comprising the binding molecules. The binding molecules can be used, for example, in the diagnosis, prophylaxis, and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses.Type: GrantFiled: January 14, 2015Date of Patent: March 14, 2017Assignee: Janssen Vaccines & Prevention B.V.Inventors: Theodorus Hendrikus Kwaks, David Adrianus Theodorus Maria Zuijdgeest, Ronald Vogels, Robert H. E. Friesen
-
Publication number: 20150274811Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. Provided are nucleic acid molecules encoding the binding molecules, their sequences, and compositions comprising the binding molecules. The binding molecules can be used, for example, in the diagnosis, prophylaxis, and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses.Type: ApplicationFiled: January 14, 2015Publication date: October 1, 2015Inventors: Theodorus Hendrikus Kwaks, David Adrianus Theodorus Maria Zuijdgeest, Ronald Vogels, Robert H.E. Friesen
-
Patent number: 8961978Abstract: The present disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. The disclosure provides nucleic acid molecules encoding the binding molecules, their sequences and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses.Type: GrantFiled: July 12, 2012Date of Patent: February 24, 2015Assignee: Crucell Holland B.V.Inventors: Theodorus Hendrikus Jacobus Kwaks, David Adrianus Theodorus Maria Zuijdgeest, Ronald Vogels, Robert Heinz Edward Friesen
-
Publication number: 20140120113Abstract: The present disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. The disclosure provides nucleic acid molecules encoding the binding molecules, their sequences and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses.Type: ApplicationFiled: July 12, 2012Publication date: May 1, 2014Applicant: Crucell Holland B.V.Inventors: Theodorus Hendrikus Jacobus Kwaks, David Adrianus Theodorus Maria Zuijdgeest, Ronald Vogels, Robert Heinz Edward Friesen
-
Patent number: 8114637Abstract: In the absence of substantial sequence overlap between a recombinant adenoviral vector and the genome of a packaging cell, helper-dependent E1-containing particles (HDEP) can be formed at low frequency. Provided are means and methods for reducing or preventing the generation of HDEP. To this purpose, novel packaging cells and methods of making these are provided.Type: GrantFiled: July 14, 2010Date of Patent: February 14, 2012Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Jans Emco Havenga, David Adrianus Theodorus Maria Zuijdgeest
-
Patent number: 8052967Abstract: Provided are methods and means to increase the stability and/or the packaging capacity of recombinant adenoviruses, by overexpression of pIX in an adenoviral packaging cell, by retaining at least a part of the E1B-55K region in the recombinant adenoviral vector or by regulating pIX with a heterologous promoter. The invention further relates to methods and means for the production of such adenoviruses on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenovirus and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products in the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.Type: GrantFiled: September 5, 2007Date of Patent: November 8, 2011Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Jans Emco Havenga, David Adrianus Theodorus Maria Zuijdgeest
-
Publication number: 20100311172Abstract: In the absence of substantial sequence overlap between a recombinant adenoviral vector and the genome of a packaging cell, helper-dependent E1-containing particles (HDEP) can be formed at low frequency. Provided are means and methods for reducing or preventing the generation of HDEP. To this purpose, novel packaging cells and methods of making these are provided.Type: ApplicationFiled: July 14, 2010Publication date: December 9, 2010Inventors: Ronald Vogels, Menzo Jans Emco Havenga, David Adrianus Theodorus Maria Zuijdgeest
-
Patent number: 7816104Abstract: In the absence of substantial sequence overlap between a recombinant adenoviral vector and the genome of a packaging cell, helper-dependent E1-containing particles (HDEP) can be formed at low frequency. The invention provides means and methods reducing or preventing the generation of HDEP. To this purpose, novel packaging cells and methods of making these are provided.Type: GrantFiled: March 20, 2006Date of Patent: October 19, 2010Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Jans Emco Havenga, David Adrianus Theodorus Maria Zuijdgeest
-
Publication number: 20080206837Abstract: Provided are methods and means to increase the stability and/or the packaging capacity of recombinant adenoviruses, by overexpression of pIX in an adenoviral packaging cell, by retaining at least a part of the E1B-55K region in the recombinant adenoviral vector or by regulating pIX with a heterologous promoter. The invention further relates to methods and means for the production of such adenoviruses on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenovirus and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products in the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.Type: ApplicationFiled: September 5, 2007Publication date: August 28, 2008Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Jans Emco Havenga, David Adrianus Theodorus Maria Zuijdgeest
-
Patent number: 7285265Abstract: The present invention provides methods and means to increase the stability and/or the packaging capacity of recombinant adenoviruses, by overexpression of pIX in an adenoviral packaging cell, by retaining at least a part of the E1B 55K region in the recombinant adenoviral vector or by regulating pIX with a heterologous promoter. The invention further relates to methods and means for the production of such adenoviruses on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenovirus and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products in the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.Type: GrantFiled: April 24, 2003Date of Patent: October 23, 2007Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Jans Emco Havenga, David Adrianus Theodorus Maria Zuijdgeest